

# ONLINE FIRST – ACCEPTED ARTICLES

Accepted articles have been peer-reviewed, revised and accepted for publication by the *SMJ*. They have not been copyedited, and are posted online in manuscript form soon after article acceptance. Each article is subsequently enhanced by mandatory copyediting, proofreading and typesetting, and will be published in a regular print and online issue of the *SMJ*. Accepted articles are citable by their DOI upon publication.

# Guidance for the prescription of human immunodeficiency virus pre-exposure prophylaxis in Singapore

Chiaw Yee Choy<sup>1,2</sup>, MBBS, MRCP, Chen Seong Wong<sup>1,2,3</sup>, MBBS, MRCP,
P Arun Kumar<sup>2</sup>, MPH, BSc(Hons), Benson Yeo<sup>4</sup>, MBBS, FAMS, Sumita Banerjee<sup>5</sup>, MSc,
Yangfa Leow<sup>6</sup>, RSW, Dariusz Piotr Olszyna<sup>7</sup>, MD, PhD, Kok Kuan Tan<sup>8</sup>, MBBS,
Rayner Kay Jin Tan<sup>9</sup>, PhD, Jonathan Ti<sup>10</sup>, MB, BCh, Roy Chan<sup>4,5,9,11</sup>, MBBS, MRCP,
Daniel Le<sup>7</sup>, Chronos Kwok<sup>5</sup>, BBus, Sophia Archuleta<sup>2,3,7</sup>, MD, ABIM

<sup>1</sup>Department of Infectious Diseases, Tan Tock Seng Hospital, <sup>2</sup>National Centre for Infectious Diseases, <sup>3</sup>Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, <sup>4</sup>National Skin Centre, <sup>5</sup>Action for AIDS, <sup>6</sup>Oogachaga, <sup>7</sup>Division of Infectious Diseases, National University Hospital, <sup>8</sup>Dr Tan Medical Center, Novena Medical Centre, <sup>9</sup>Saw Swee Hock School of Public Health, National University of Singapore, <sup>10</sup>Dr Tan & Partners @ Robertson Walk, <sup>11</sup>Department of Sexually Transmitted Infections Control Clinic, Singapore

**Correspondence**: Dr Chen Seong Wong, Consultant, National Centre for Infectious Diseases, 16 Jalan Tan Tock Seng, Singapore 308442. Chen Seong Wong@ncid.sg

# Singapore Med J 2022, 1–18

https://doi.org/10.11622/smedj.2022043

Published ahead of print: 3 April 2022

More information, including how to cite online first accepted articles, can be found at: http://www.smj.org.sg/accepted-articles

#### WHAT IS NEW IN THE GUIDANCE?

#### **Special Clinical Scenarios**

- Under raised creatinine after starting PrEP: new data pertaining to the safety of TDF/FTC has been added. TAF/FTC has also been added as a potential regimen for cis-gender men who have sex with men and trans-gender women who have sex with men with eGFR between 30ml/min and 60ml/min.
- Under hepatitis B virus infection: TAF/FTC has also been added as a potential regimen for cis-gender men who have sex with men and trans-gender women who have sex with men with eGFR between 30ml/min and 60ml/min and have chronic HBV infection.
- A new section entitled "Interpretation of HIV antigen-antibody test" has been added to aid PrEP prescribers on what to do in the setting of an indeterminate HIV antigen-antibody test.

#### Table II: Contraindications to PrEP

• Under known impairment of renal function, further clarifications have been made that PrEP is contraindicated in individuals with estimated creatinine clearance <60 ml/min who are considering TDF/FTC and estimated creatinine clearance < 30ml/min for individuals eligible for TAF/FTC.

### Table III: How should PrEP be taken?

• The appropriate use of TAF/FTC has been included in this table.

#### Table V: What should be done after PrEP is started?

- Under serum creatinine: repeat creatinine is only required for all individuals 1-3 months after starting PrEP. However, subsequent creatinine monitoring is only required at least annually for those with kidney related co-morbidities and age 50 years and above.
- Under anti HCV monitoring: changes have been made to include people who use drugs.

#### INTRODUCTION

Every year, approximately 1.7 million people are diagnosed with human immunodeficiency virus (HIV) infection.<sup>(1)</sup> While the availability of highly active combination antiretroviral therapy (cART) has drastically improved the quality of life and life expectancy of people living with HIV,<sup>(2)</sup> 680 000 people still died of acquired immunodeficiency syndrome (AIDS)-related illness across the globe in 2020.<sup>(1)</sup>

The number of new cases of HIV infection reported each year in Singapore remained fairly constant between 2008 and 2017, and ranged from 400-500 new cases annually. There has since been a decreasing trend in the number of new cases since 2018, with 261 new cases being reported among Singapore residents in 2020. This decrease is likely to be due to multiple factors, including ongoing campaigns focusing on conventional behavioural prevention strategies such as condom use, as well as biomedical strategies such as widespread use of highly effective cART for HIV-infected individuals for prevention of transmission. In addition, from 2020, the arrival of the COVID-19 pandemic has resulted in the implementation of a series of safe-distancing measures, which may have played a part in reducing the transmission of HIV infection.

HIV is primarily transmitted via sexual intercourse, exposure to infected blood or perinatal transmission. In Singapore, sexual intercourse is the main mode of transmission, with 95% of the cases diagnosed in 2020 acquiring HIV infection via sexual intercourse. HIV prevention strategies therefore include a combination of methods, including the national framework of "ABCD", which stands for: A (Abstinence), B (Be Faithful), C (Correct and Consistent condom use) and D (early Detection and treatment for viral suppression). The most effective way to prevent HIV infection is to remain faithful to one's spouse/ partner and to avoid casual sex, and sex with sex workers. Persons engaging in high-risk sexual behaviour, such as having multiple sexual partners or engaging in casual or commercial sex, are strongly advised to use condoms to reduce their risk of HIV infection and other sexually transmitted infections (STI). Condoms should be used consistently and correctly during every sexual encounter.

Pre-exposure prophylaxis (PrEP) is a supplementary preventive measure against HIV. In recent years, trials involving PrEP have suggested that it may also be considered in specific groups as an additional strategy to prevent HIV infection. PrEP involves the use of anti-retroviral drugs (the combination of tenofovir disoproxil fumarate or TDF, and emtricitabine

or FTC, co-formulated as a single pill known as Truvada<sup>TM</sup> or tenofovir alafenamide or TAF and FTC, co-formulated as a single pill known as Descovy<sup>TM</sup> or bioequivalent generics) by HIV-negative individuals at high risk of acquiring HIV infection to prevent transmission and its use has been increasing worldwide.

Recognising that physicians in Singapore may wish to prescribe PrEP for their patients, in May 2019, a PrEP Workgroup, convened by the National HIV Programme (NHVIP), met to develop guidance for physicians on how to do so. The Workgroup consisted of clinicians and researchers with expertise in HIV, as well as representatives of community-based organisations involved in Singapore's HIV response and adopted a consensus decision making process. The Workgroup's guidance is an updated adaptation of current major international guidelines on PrEP from the World Health Organisation (WHO),<sup>(8)</sup> the US Centers for Disease Control and Prevention (CDC),<sup>(9)</sup> British HIV Association (BHIVA),<sup>(10)</sup> the Australasian Society for HIV Medicine (ASHM),<sup>(11)</sup> European AIDS Clinical Society<sup>(12)</sup> and the Taiwan AIDS Society,<sup>(13)</sup> as well as a previous local guideline created by the PrEP taskforce in April 2018. The guidance aims to: assist clinicians in their evaluation of patients who are seeking PrEP; and assist clinicians in commencing and monitoring their patients on PrEP. It is hoped that the development and dissemination of this guidance will be helpful for physicians who are keen to use PrEP as an additional tool to prevent HIV infection.

#### RECOMMENDATIONS FOR THE USE OF PrEP IN SINGAPORE

Providers need to obtain and document the following important aspects of history-taking and discussion during their initial consultation with patients:

- Thorough sexual history, including timing of last unprotected sex acts
- HIV and STI screens in the last year, and date of the last HIV test
- History of bone or renal disease

- Importance of 3-monthly HIV/STI screens
- Importance of taking TDF/FTC or TAF/FTC for PrEP as directed
- Options for source of TDF/FTC or TAF/FTC for PrEP
- Risk reduction including information and support for recreational drug use as appropriate Prior to starting PrEP, all clients will need a baseline 4<sup>th</sup> generation HIV test to exclude HIV infection. The initiation of PrEP in the context of undiagnosed HIV infection puts an individual at risk of developing antiretroviral resistance. If they test positive for HIV, PrEP should not be started and they should be linked to care for HIV treatment instead. PrEP should also be stopped immediately if clients show early signs of HIV seroconversion while on PrEP.

#### SPECIAL CLINICAL SCENARIOS

There are certain clinical scenarios which physicians need to take note of when prescribing PrEP.

#### **Hepatitis B virus (HBV) infection**

TDF and FTC are both active against HIV and HBV infections. All individuals who test positive for the hepatitis B surface antigen (HBsAg) will need a baseline HBV DNA quantitative assay to determine the level of replication prior to starting PrEP. (14) HBV DNA levels should be monitored 6-12 monthly in these cases.

As TDF and FTC can treat HBV infection, these individuals should be started on daily PrEP rather than on demand PrEP. It is important to emphasize adherence to the regimen to prevent reactivation of HBV infection with potential acute liver injury and to reduce the risk of developing TDF resistant HBV infection. (15)

In 2020, the DISCOVER trial found that TAF/FTC is non-inferior to TDF/FTC for the prevention of HIV infection in adult cis-gender men who have sex with men and transgender women who have sex with men.<sup>(16)</sup> Similar to TDF, TAF can treat HBV infection and cisgender men who have sex with men and transgender women who have chronic HBV infection starting on PrEP should be on the daily PrEP regimen rather than on demand PrEP.<sup>(17)</sup>

If PrEP is no longer required for HIV prevention, a clinical decision will have to be made on whether TDF or TAF is needed for treatment of HBV infection. While acute flares from reactivation of HBV infection have been seen in HIV-infected individuals who stop TDF and other medications used to treat HBV infection, similar flares have not been documented in individuals on PrEP.<sup>(18,19)</sup> Nevertheless, given the potential risk involved, these individuals should be monitored closely by an experienced clinician after stopping PrEP.

#### Raised creatinine after starting PrEP

TDF has been associated with increased renal toxicity and osteoporosis when used as regular treatment for people living with HIV, (20,21) but the same effect has not been seen in patients on PrEP. A metanalysis of 13 randomised trials comparing the use of TDF/FTC or TDF alone as PrEP versus placebo found no significant differences in risk of grade 3/4 clinical adverse events, bone or renal adverse outcomes. (22) In cases where there was substantive decline (i.e. more than 25% of baseline) in the estimated glomerular filtration rate (eGFR), cessation of PrEP resulted in normalization of the eGFR in almost all patients. (23) In addition, a metanalysis of global programme data found that <1% who were screened before starting oral PrEP had abnormal creatinine clearance levels and less than 3% of oral PrEP users experienced a decline in creatinine clearance to <60 mL/min. Older individuals, especially those over 50 years, with baseline creatinine clearance of <90 mL/min and with kidney-related comorbidities such as diabetes or hypertension, had a higher probability of declining to abnormal levels of

creatinine clearance.<sup>(8)</sup> Less than 1% of oral PrEP users younger than 30 years experience abnormal creatinine clearance.<sup>(8)</sup> In view of the above data, the population of individuals who require creatinine monitoring and the frequency of creatinine monitoring has been changed to better adapt the above findings (refer to table IV and V).

However, there is no data concerning the use of PrEP for individuals with eGFR < 60ml/min. Hence, the use of TDF should still be stopped in individuals whose eGFR falls to <60ml/min. For cis-gender men who have sex with men and trans-gender women who have sex with men with eGFR between 30ml/min and 60ml/min, there is now an option to use TAF/FTC instead. (24) As there is limited data on the use of TAF in patients with eGFR < 30mL/min, most international guidelines have advised avoiding the use of TAF in these patients.

#### High risk exposures within 72 hours

It is important to ensure that individuals are HIV negative prior to starting PrEP. In individuals who have high risk exposure within the last 72 hours, it may be appropriate to consider the use of post exposure prophylaxis (PEP) prior to the use of PrEP. As it takes up to 72 hours for HIV to be detected in regional lymph nodes and up to 5 days to be detected in blood, the use of PEP can help to prevent the acquisition of HIV infection following exposure by inhibiting viral replication. (25) PEP is likely to be ineffective if started beyond 72 hours. In such cases, HIV testing should be repeated 4 weeks later to definitively exclude HIV infection. However, if the individual is keen to start PrEP immediately, HIV RNA viral load testing should be done to exclude acute HIV infection.

# Interpretation of HIV antigen-antibody testing results

All individuals should have a 4<sup>th</sup> generation HIV test (either routine HIV EIA (enzyme-linked immunoassay) within the past 4 weeks OR rapid point-of-care finger-prick blood test on the day of consultation if no concern of recent exposure. If a HIV antigen-antibody test returns as indeterminate, this could suggest very early HIV infection (i.e. acute HIV infection or HIV seroconversion) or a false positive result. (26) In these instances, a HIV RNA viral load may be considered and/or a repeat HIV antigen-antibody test. PrEP should NOT be started in these instances and physicians can consider making a referral to an infectious disease specialist for further evaluation.

Individuals with high-risk exposure who are non-adherent to the PrEP regimen are still at risk contracting HIV infection. However, HIV-1 seroconversion may be delayed while patient is partially compliant to PrEP.<sup>(27)</sup> Hence, an indeterminate HIV antigen-antibody test in these individuals should raise suspicions for possible HIV infection. These individuals should also stop PrEP to prevent development of potential resistance and referred to an infectious disease specialist from further evaluation.

Table I: Who may be suitable for PrEP.

Who may be suitable for PrEP?	Additional Considerations
Sexual partner of someone with HIV who is not on suppressive	HIV viral suppression defined as plasma viral load < 200 copies/mL
antiretroviral therapy	for $\geq 6$ months
Vaginal or anal intercourse without the consistent use of condoms	If the high-risk exposure is after 72 hours but within 28 days of
with more than one partner in the last six months	window period, HIV testing should be repeated after 4 weeks prior to
	starting PrEP. Alternatively, HIV RNA viral load can be done if
	patient is keen to start PrEP immediately.
Sexually transmitted infection in the last six months (laboratory	Particularly syphilis
confirmed, self-reported or received treatment)	
Received HIV post-exposure prophylaxis in the last six months	
Reported concerns about consistent use of condoms in the future	E.g. has difficulties using condoms
Engage in sexual activities under the influence of alcohol or other	Or indicate that they may have such behaviour
drugs	
Requesting for PrEP- case by case basis	E.g. left a monogamous partnership and will likely be having
	condomless sex in future

#### Table II: Contraindications to use of PrEP.

## **Contraindications to use of PrEP**

- Known HIV infection
- Clinical syndrome suggestive of acute HIV infection/HIV seroconversion (please refer to Special Clinical Scenarios section Interpretation of HIV antigen-antibody testing results)
- Known impairment of renal function (estimated creatinine clearance < 60 ml/min for individuals considering TDF/FTC and estimated creatinine clearance < 30ml/min for individuals eligible for TAF/FTC)
- Allergy or other known contraindication to any of the drugs in the PrEP regimen

Table III: How should PrEP be taken?

Methods	Suitable populations	Administration
Daily PrEP	All who have indications for PrEP	<ul> <li>All individuals: daily dosing of co-formulated TDF/FTC</li> <li>Cis-gender men who have sex with men and trans-gender women who have sex with men: these individuals can also use daily dosing of co-formulated TAF/FTC</li> </ul>
		<ul> <li>Note: <ul> <li>Needs to be taken for 7 days before high levels of protection are achieved for both vaginal and rectal exposure to HIV.</li> <li>Alternative regimens such as taking PrEP four times a week is not recommended</li> <li>TAF/FTC can be only be used in cis-gender men who have sex with men and trans-gender women who have sex with men as daily PrEP regimen.</li> </ul> </li> </ul>
On-Demand PrEP	On-demand PrEP has only been investigated and is recommended in cis-gender men who have sex with men	<ul> <li>A double dose (two tablets) of co-formulated TDF/FTC to be taken 2-24 hours before potential sexual exposure, to be followed by single doses 24 and 48 hours after the initial dose.</li> <li>When potential exposure is sustained for more than a 24-hour period, 1 tablet per day should be taken until the last exposure followed by the 2 post exposure tablets.</li> </ul>
		Note: - TAF/FTC cannot be used in on-demand PrEP regimen

Table IV: What should be done at first consultation?

What should be done at	Example	Additional Considerations
first consultation?		
Ensure that patient is HIV-	Using a 4 <sup>th</sup> generation HIV test (either routine	Lab based HIV 4th General EIA test is preferred
negative	HIV EIA (enzyme-linked immunoassay) within	
	the past 4 weeks OR rapid point-of-care finger-	
	prick blood test <b>on the day of consultation</b> if no	
	concern of recent exposure	
	If recent high-risk exposure (within the past 72	Consider Post Exposure Prophylaxis
	hours) consider PEP and re-test after 28 days	
	If high-risk exposure after 72 hours but within	
	past 28 days, repeat HIV testing after 4 weeks	
	IF patient keen to initiate PrEP immediately	
	consider HIV RNA (viral load) testing	
Baseline renal function	Serum creatinine	Estimated creatinine clearance can be calculated using the
testing		modified Cockcroft-Gault equation
	Urinalysis for proteinuria	Only for patients with pre-existing risk for renal
		impairment, e.g. diabetes, hypertension
Hepatitis B screening	Hepatitis B surface antigen (HBsAg) and	Vaccination against hepatitis B should be offered to non-
	antibody (anti-HBs)	immune individuals. If patients test positive for hepatitis B,
		they should be considered for treatment and <u>not</u> be offered
		on-demand PrEP.
Offer Hepatitis C screening	Hepatitis C antibody (anti-HCV)	Referral for hepatitis C treatment if positive
Offer STI screening and	Syphilis screening	
treatment		
	Other bacterial STIs (gonorrhoea, chlamydia,	At relevant and appropriate sites based on sexual history or
	etc)	consider three in one testing as per site availability
		(urethral, rectal, pharyngeal, etc)

Offer pregnancy screening	Urinary beta-HCG	Contraception should be discussed and provided for women
		who are on PrEP and who do not wish to become pregnant
Prescribe PrEP	Prescription should not exceed 3 months or 90	A printed and endorsed prescription should be provided
	days with no automatic refills	
Other services	Joint development of plan for effective PrEP use	
	(including deciding on daily versus on-demand	
	PrEP)	
	Vaccination against hepatitis A, B and human	
	papillomavirus as indicated	
Counselling	Efficacy of PrEP	Key Message: PrEP is highly effective if taken as
		prescribed as part of an overall HIV prevention strategy
		(including the use of condoms)
	Adherence counselling	Key Message: It is important to take PrEP every day (for
		daily PrEP) and according to the schedule (for on-demand
		PrEP) for it to be effective.
	Engagement in care	Key Message: It is important to return for visits to get
		tested for HIV and assess for side effects to medication as
		well as to obtain new prescription so that PrEP is not
		interrupted.
	Sexual health counselling	Key Message: PrEP does not prevent other STIs, and
		regular testing and treatment for other STIs is needed to
		maintain sexual health. PrEP also does not prevent
		pregnancy and contraception should be used to prevent
		pregnancy if needed.

**Table V: What should be done after PrEP is started?** 

What should be done after PrEP is started?	Tests/agenda to be done	Additional Considerations
Consider reviewing the patient at 4 weeks for the following, either in clinic or using telemedicine	Consider repeat HIV testing at 4 weeks via use of 4 <sup>th</sup> generation HIV test	Especially if there are concerns about adherence to PrEP in the first 4 weeks or if there was a high-risk exposure 3 days or more prior to PrEP initiation  Check for adherence to PrEP  Confirm that daily OR on-demand regimens are being taken appropriately  Check for side-effects
Review 3-6 monthly thereafter	3 <sup>rd</sup> /4 <sup>th</sup> generation HIV test (either routine HIV EIA OR rapid POCT finger-prick blood test) 3 monthly Serum Creatinine	For individuals with co-morbidities or 50 years and above
	All individuals should get a repeat creatinine 1-3 months after starting PrEP.  In individuals younger than 50 years old without	with routine creatinine monitoring done in other settings, PrEP providers can consider using these results in their clinic review instead of obtaining a separate serum creatinine if appropriate.
	any co-morbidities, nil further creatinine monitoring is required if the repeat creatinine test is normal.	
	Individuals with kidney related co-morbidities or age 50 years and above should have a repeat serum creatinine check at least once every 12 months.	

	STI screening and treatment  Anti-HCV 12 monthly Consider 3 monthly with very high-risk behaviour	Syphilis, gonorrhoea and chlamydia screening 3 – 6 monthly Frequency of screening depends on patient-reported sexual risk behaviour Especially for PrEP services provided to men who have sex with men and people who use drugs.
	Urinary beta-HCG 3 monthly	
Prescribe PrEP	Prescription should not exceed 3 months or 90 days with no automatic refill	For patients obtaining medications from external sources, a printed and endorsed prescription should be provided
Other services	Vaccination against hepatitis A, B and human papillomavirus if not previously offered  Contraception for women on PrEP who do not wish to become pregnant	
Counselling	Adherence counselling Engagement in care Sexual health counselling	Reinforce Key Messages as outlined in Table 4
Assess if PrEP is still needed	The need for continued PrEP should be determined based on assessment of the patient's risk of HIV infection 12 monthly	Patients should continue taking daily PrEP for 28 days after the last sexual exposure putting them at risk of HIV infection before discontinuing PrEP. Only cis-gender MSM can safely stop PrEP after taking a dose 24 and 48 hours after last at-risk exposure.
Linkage to care for patients who seroconvert	All patients who test positive for HIV should be referred for treatment at a HIV care centre on an urgent basis	HIV-infected patients can be started on HIV treatment without interruption

Table VI: What should be done if PrEP is discontinued?

What should be done if	Tests/agenda to be done	Additional Considerations
PrEP is discontinued?		
Assess HIV status	HIV testing	
Hepatitis B testing and	Consider repeat HbsAg testing on planning to	Patients who are HbsAg-positive and stop PrEP should have
treatment considerations	discontinue PrEP unless there is documented	their liver function and hepatitis B viral load monitored after
	immunity	cessation of PrEP as there is a risk of reactivation of
		infection
Counselling	Advice on re-initiation of PrEP	Patients should be counselled that they should consider
		reinitiation of PrEP if the risk of HIV infection should
		become present again, e.g.
		- Entering a period of engaging in unprotected sex
		- Leaving a long-term relationship
		- Starting a serodiscordant relationship with a partner
		who is yet to be virally suppressed or with a partner
		of unknown HIV status
		- Other risk factors for HIV acquisition

#### REFERENCES

- Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV & AIDS statistics

   2021 fact sheet. In: UNAIDS Global HIV & AIDS statistics [Internet]. 2021. Available
   at: <a href="https://www.unaids.org/sites/default/files/media">https://www.unaids.org/sites/default/files/media</a> asset/UNAIDS FactSheet en.pdf.
   Accessed July 23, 2021.
- Montaner JS, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated
  with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the
  "HIV Treatment as Prevention" experience in a Canadian setting. PLoS One 2014;
  9:e87872.
- Update on the HIV/AIDS situation in Singapore 2018. In: Ministry of Health Resources & statistics [Internet]. Available at: <a href="https://www.moh.gov.sg/resources-statistics/infectious-disease-statistics/hiv-stats/update-on-the-hiv-aids-situation-in-singapore-2018-(june-2019)">https://www.moh.gov.sg/resources-statistics/infectious-disease-statistics/hiv-stats/update-on-the-hiv-aids-situation-in-singapore-2018-(june-2019)</a>. Accessed October 13, 2020.
- 4. Update on the HIV/AIDS situation in Singapore 2019 (JUNE 2020). In: Ministry of Health Resources & statistics [Internet]. 2020. Available at: <a href="https://www.moh.gov.sg/resources-statistics/infectious-disease-statistics/hiv-stats/update-on-the-hiv-aids-situation-in-singapore-2019-(june-2020)">https://www.moh.gov.sg/resources-statistics/hiv-stats/update-on-the-hiv-aids-situation-in-singapore-2019-(june-2020)</a>. Accessed October 13, 2020.
- 5. Update on the HIV/AIDS situation in Singapore 2020 (June 2021). In: Ministry of Health Resources & statistics [Internet]. Available at: <a href="https://www.moh.gov.sg/resources-statistics/infectious-disease-statistics/hiv-stats/update-on-the-hiv-aids-situation-in-singapore-2020-(june-2021)">https://www.moh.gov.sg/resources-statistics/hiv-stats/update-on-the-hiv-aids-situation-in-singapore-2020-(june-2021)</a>. Accessed July 23, 2021.
- 6. Stricter safe distancing measures to prevent further spread of COVID-19 cases. In: Ministry of Health Resources & statistics [Internet]. Available at: <a href="https://www.moh.gov.sg/news-highlights/details/stricter-safe-distancing-measures-to-prevent-further-spread-of-covid-19-cases">https://www.moh.gov.sg/news-highlights/details/stricter-safe-distancing-measures-to-prevent-further-spread-of-covid-19-cases</a>. Accessed July 23, 2021.

- 7. Prevent HIV with ABCD. In: healthhubsg2020 [Internet]. 2020. Available at: <a href="https://www.healthhub.sg">www.healthhub.sg</a>. Accessed October 13, 2020.
- 8. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. In: World Health Organization Publications [Internet]. 2021. Available at: https://www.who.int/publications/i/item/9789240031593. Accessed July 23, 2021.
- Preexposure prophylaxis for the prevention of HIV infection in the United States- 2017 update. In: Centers for Disease Control and Prevention HIV risk and prevention [Internet].
   Available at: <a href="https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf">https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf</a>. Accessed October 13, 2020.
- 10. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018 In: British HIV Association current guidelines [Internet]. 2018. Available at: https://www.bhiva.org/PrEP-guidelines. Accessed October 13, 2020.
- 11. Wright E, Grulich A, Roy K, et al. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. J Virus Erad 2018; 4:143-59.
- 12. European AIDS Clinical Society (EACS). Guidelines Version 10.1October 2020 In: EACS Guidelines [Internet]. Available at: <a href="https://www.eacsociety.org/media/guidelines-10.1\_30032021\_1.pdf">https://www.eacsociety.org/media/guidelines-10.1\_30032021\_1.pdf</a>. Accessed August 18, 2021.
- 13. Yen-Hao Chu I, Wen-Wei Ku S, Li CW, et al. Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention 2018 update. J Microbiol Immunol Infect 2020; 53:1-10.
- 14. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373:582-92.
- 15. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 53:1854-63.

- 16. Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet 2020; 396:239-54.
- 17. Childs-Kean LM, Egelund EF, Jourjy J. Tenofovir Alafenamide for the treatment of chronic hepatitis B monoinfection. Pharmacotherapy 2018; 38:1051-7.
- 18. Solomon MM, Schechter M, Liu AY, et al. The safety of tenofovir-emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis B. J Acquir Immune Defic Syndr 2016; 71:281-6.
- 19. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis 2006; 43:904-10.
- 20. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011; 2011:354908.
- 21. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC. Tenofovir-associated bone density loss. Ther Clin Risk Manag 2010; 6:41-7.
- 22. Pilkington V, Hill A, Hughes S, Nwokolo N, Pozniak A. How safe is TDF/FTC as PrEP?

  A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. J Virus Erad 2018; 4:215-24.
- 23. Drak D, Barratt H, Templeton DJ, O'Connor CC, Gracey DM. Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service. PloS One 2019; 14:e0210106
- 24. Arribas JR, Thompson M, Sax PE, et al. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: Week 144 results. J Acquir Immune Defic Syndr 2017; 75:211-8.

- 25. Sultan B, Benn P, Waters L. Current perspectives in HIV post-exposure prophylaxis. HIV AIDS (Auckl) 2014; 6:147-58.
- 26. Mahajan VS, Pace CA, Jarolim P. Interpretation of HIV serologic testing results. Clin Chem 2010; 56:1523-6.
- 27. Donnell D, Ramos E, Celum C, et al. The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. AIDS 2017; 31:2007-16.